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Summary 
The objective of this study was to evaluate the changes in some bacterial species of 
colonic microbiota, the clinical signs and the intestinal changes in mice with 2,4,6-
trinitrobenzenesulfonic acid (TNBS)-induced colitis.  
CD-1 male mice were randomly divided into three groups and inoculated intrarectally 
with saline, ethanol or TNBS solutions. Ethanol and TNBS treatments induced weight 
loss accompanied by mild and severe inflammation of the colon mucosa, respectively. 
However, TNBS-treated mice displayed significant differences compared to the saline 
group in terms of disease activity index and histological scoring. Both ethanol and 
TNBS groups showed an increased prevalence of Escherichia coli and Clostridium spp., 
a decrease in Lactobacilli and Bifidobacteria counts, as well as changes in the relative 
proportions of bacteria in the colon.  
The results confirm the validity of TNBS treatment to study the mechanisms involved 
in the pathogenesis and progression of inflammatory bowel diseases (IBD) in CD-1 
mice. Gut microbiota may become a diagnostic biomarker with therapeutic potential 
for IBD in the future. 
Introduction 
Inflammatory bowel diseases (IBD) are chronic, recurrent and multifactorial conditions 
affecting the gastro-intestinal tract. Although the aetiology of IBD is still not fully un-
derstood, it involves a complex interaction between genetic, luminal and environ-
mental factors, including diet, cigarette smoke and drug exposure, infections, geogra-
phy and stress, that trigger an inappropriate mucosal immune response. Changes in 
the composition of intestinal microbiota and an abnormal immune response to gut mi-
croorganisms are likely to be the key fac-
tors in the onset and progression of IBD. 
IBD include ulcerative colitis (UC) and 
Crohn’s disease (CD), which can be dis-
tinguished by the localization of the in-
flammatory changes in the digestive sys-
tem, i.e. the portion of the intestinal wall 
affected by inflammation and microbial 
perturbations. UC is confined to the co-
lon, while CD may affect any part of the 
digestive tract. The implications of micro-
bial involvement or causality in IBD are 
still unclear [1]. The complex microbial 
population of the intestinal tract plays an 
important role in host nutrition and 
health, since different bacterial species 
establish a rich interaction network in-
volving mutualism, symbiosis and patho-
genicity [2]. Colonization occurs mainly 
in the colon that typically harbors more 
than 500 different species of bacteria [3]. 
The microbiota exerts various physiologi-
cal functions, including: i) inhibition of 
pathogen growth; ii) mucosal barrier 
function; iii) synthesis of compounds 
useful for the trophism of colon mucosa, 
such as butyric acid, from unabsorbed 
carbohydrates; iv) modulation of intesti-
nal innate and adaptive immune system; 
and v) synthesis of several nutrients, 
such as amino acids and vitamins B and 
K, and mineral absorption. In healthy 
subjects, specific mechanisms regulate 
the immunological tolerance of the host 
to intestinal microbiota and their meta-
bolic products. The interaction between 
the host and specific bacterial strains can 
induce a tolerogenic response to the in-
testinal microflora through production of 
regulatory T cells (Treg) and IgAs, sup-
pression of cellular pathways related to 
the synthesis of pro-inflammatory cyto-
kines, and, finally, production of anti-
inflammatory cytokines and antimicrobial 
peptides [4].  
On the other hand, an abnormal intesti-
nal flora is responsible for a large num-
ber of negative effects in the host. There 
is mounting evidence that microbiota can 
induce conditions like IBD, obesity, and 
type I diabetes [5]. Resident bacteria 
play an important role in initiating and 
perpetuating intestinal inflammation in 
IBD. It is well known that the quality and 
quantity of intestinal microbiota vary 
with disease; some bacterial species may 
promote the development of a specific 
disease, while concurrently protecting the 
host from another disorder. Moreover, 
the mechanistic potential of bacterial 
species may also differ between the vari-
ous parts of the gut. Indeed, there are 
evidence that intestinal microbiota is 
greatly different in healthy individuals 
compared to UC and CD patients. Fur-
thermore, to date, the various studies 
carried out on IBD have not managed to 
identify a single specific bacterial species 
as a cause for this disease [6]. Numerous 
studies performed in human and animal 
models have investigated changes in the 
composition of microbiota in several gas-
tro-intestinal inflammatory diseases, in-
cluding IBD, using different approaches 
[7,8]. Currently, different types of meth-
ods are being employed for analyzing gut 
microbiota composition, including bacte-
rial cultures (conventional microbiological 
techniques), and the most recent and 
sophisticated molecular biological meth-
ods, such as fluorescence in situ hybridi-
zation, terminal restriction fragment 
length polymorphism, and metagenomics 
approaches [9]. Cultivation-based analy-
sis is the most simple and inexpensive 
way to quantify gut microbiota. While this 
technique does not allow the detection of 
some species, it can be used to evaluate 
physiological parameters, and it does not 
require extensive bio-informatic analy-
ses. IBD patients present a reduction in 
biodiversity and a depletion of some bac-
terial phyla, observed in feces and mu-
cosa-associated microbiota [9]. Specifi-
cally, several authors have reported a 
reduction in the relative abundance of 
“beneficial bacteria”, such as Bifidobacte-
ria and Lactobacilli, and an increase in 
potentially dangerous bacteria, such as E. 
coli, in gut inflammatory diseases, includ-
ing IBD [10,11]. Nevertheless, at the 
moment it is unclear whether dysbiosis is 
a cause or a consequence of IDB. To un-
derstand the pathogenesis of IBD and 
identify potential therapeutic agents, sev-
eral chemical- and hapten-induced colitis 
models have been used, including the 
TNBS-induced colitis model [12]. This is 
an experimental model of intestinal in-
flammation that induces IBD-like histo-
COLON MICROBIAL COMPOSITION AND COLITIS, p. 166 EMBJ, 11 (23), 2016 — www.embj.org 
logical and biochemical features. In par-
ticular, TNBS in mice closely mimics hu-
man IBD both histopathologically [13] 
and clinically [14]. It is currently thought 
that intestinal inflammation is induced by 
two-step process. Firstly, ethanol impairs 
epithelial barrier functions; TNBS then 
haptenizes intestinal antigens and micro-
bial proteins, triggering the host immune 
system. Moreover, intestinal microbiota 
dysbiosis related to TNBS-induced en-
terocolitis has been found in zebrafish 
[15] and rat [16] IBD-like models. How-
ever, the effects of TNBS treatment on 
the colon microbiota of CD-1 mice still 
need to be elucidated.  
The objective of this study was to evalu-
ate the changes in some bacterial spe-
cies of colonic microbiota in relation to 
the clinical signs and intestinal changes 
induced by TNBS in CD1 mice.  
 
Materials and Methods  
Animals 
Twenty-seven CD-1 strain male mice 
aged 5 to 6 weeks (weighing 26-34g) 
were acquired from Harlan Laboratories 
S.r.l. (Correzzana D’Adda, Milan, Italy). 
Mice were housed in a controlled envi-
ronment in terms of temperature (22°C) 
and photoperiods (12:12-hour light/dark 
cycle), and allowed unrestricted access 
to standard mouse chow and tap water. 
After 10 days of acclimatization, mice 
were randomly divided into three groups 
(n=9 per group) and inoculated intrarec-
tally with saline (Saline group), 50% 
ethanol (Ethanol group), or TNBS solu-
tion (TNBS group). All experiments con-
formed to the Guide for the Care and Use 
of Laboratory Animals, published by the 
US National Institutes of Health (NIH 
publication No. 85-23, revised 1996). 
Animal care was in compliance with cur-
rent Italian regulations (Ministerial Dec-
laration 116/92) and the European Eco-
nomic Community rules (O.J. of Euro-
pean Commission L 358/1 12/18/1986). 
The experimental design was approved 
by the Ethical Committee for Animal Ex-
perimentation of the University of Pe-
rugia, Italy.  
Induction of inflammation 
Mice were lightly anesthetized with 
isoflurane (Merial, Milan Italy) and TNBS 
(1.5 mg/mouse) dissolved in 50% etha-
nol was administered intrarectally via a 
catheter (2 biological instruments, Ba-
sozzo, Varese, Italy) equipped with a 1-
ml syringe. The catheter was inserted 
about 3 cm into the rectum, and a total 
volume of 150 µl TNBS was adminis-
tered. In order to distribute the TNBS 
within the colon, the mouse was held in a 
vertical position with the head down for 1 
min following the injection. Mice from the 
other groups were treated with the same 
procedure and an equivalent volume of 
saline or ethanol. Mice were sacrificed 3 
days after TNBS administration. Body 
weight (BW) was measured at TNBS/
saline/ethanol treatment (T0) and at the 
end of the experimental period (T1)  
Determination of disease activity index 
(DAI)  
DAI was determined using the method 
described by Murano et al. [17], combin-
ing weight loss, stool consistency and 
bleeding scores. BW changes were calcu-
lated as the difference between BW at T1 
and T0. Diarrhoea was assessed daily 
through the presence or absence of fae-
cal material adhering to anal fur and con-
firmed during autopsy through the pres-
ence or absence of faecal pellet in the 
rectum. A 4-point scale was used, with 0 
corresponding to a normal faecal pellet 
and 4 corresponding to frank diarrhoea. 
Rectal bleeding was evaluated daily 
through the presence or absence of visi-
ble blood in the faecal material, and dur-
ing autopsy through the presence or ab-
sence of gross colonic or rectal bleeding, 
and scored as 0 for negative and 4 for 
gross bleeding.  
Tissue processing 
All surviving mice were euthanized by 
cervical dislocation 3 days after the in-
trarectal treatment. At autopsy, a gross 
evaluation of the digestive tract was car-
ried out. The intact gastrointestinal tract 
was immediately excised from anus to 
oesophagus. The large bowel was subdi-
vided into caecum, colon and rectum. 
Colon was opened longitudinally. The lu-
minal materials were removed, immedi-
ately placed into an anaerobic chamber 
and dissolved in sterile pre-reduced PBS 
for the bacteriological assays. Colon tis-
sues were cleaned with saline and sev-
eral samples were collected for the histo-
logical evaluation and fixed in a 10% 
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buffered formalin solution. 
Histology 
After an overnight fixation in formalin, 
tissues were dehydrated in alcohol and 
cleared by xylene before embedding 
them in paraffin wax. 4-5 μm sections 
were stained with hematoxylin and eosin 
(H&E) to evaluate structural and mor-
phological colon alterations.  
Histological scoring  
Histological scoring was based on a 
modified semiquantitative score system 
described by McCafferty et al. [18]. 
Samples were scored in blind. Colonic 
changes were graded as follows: extent 
of mucosal architecture destruction, 
presence and degree of cellular infiltra-
tion, extent of muscle thickening, pres-
ence of crypt abscesses, and degree of 
goblet cell depletion. For each feature, a 
score of 0, 1, 2, or 3 was attributed, cor-
responding to normal, mild, moderate, 
and extensive changes, respectively. The 
scores for each feature were summed 
up, producing a maximum overall score 
of 15. 
Microbiological analysis 
Colon contents were removed asepti-
cally, immediately placed into an anaero-
bic chamber, and dissolved in sterile pre-
reduced PBS. A sterile stick was used to 
transfer 1 g of intestinal contents into a 
sterile test tube together with 2 ml 0.9% 
sterile saline solution. The stool was 
pressed and mixed into this solution and 
the tube was brought to volume (10 ml) 
with 0.9% sterile saline solution. Each 
sample (0.1 ml) was serially diluted via 
10-fold dilutions. Starting from the low-
est concentration, dilutions were plated 
and cultured on different media in tripli-
cate, using the spread plate method. 
Chromocult agar and Bile Esculin Azide 
agar were used for the enumeration of E. 
coli/Coliforms and Enterococci, respec-
tively. All the plates were aerobically in-
cubated at 37°C for 24-48hr. Reinforced 
Clostridial agar enriched with 5% sheep 
blood and 1 mg/ml vitamin K1. Brain 
Heart Infusion agar, Mann Rogosa 
Sharpe agar (MRS) and modified MRS 
agar, enriched with (0.3% (w/v) sodium 
propionate, 0.2% (w/v) lithium chloride, 
0.05% (w/v) cysteine hydrochloride and 
5% (v/v) defibrinated sheep blood were 
used for the enumeration of Clostridium 
spp, total anaerobes, Lactobacillus spp. 
and Bifidobacterium spp., respectively. 
Anaerobic incubation was carried out in 
anaerobic jars (Oxoid) at 37°C for 48-72 
hr. Anaerobic conditions were obtained 
using Anaerogen (Oxoid) and confirmed 
using methyl blue strips as oxidation-
reduction indicator. The number of colo-
nies was counted and all the data are ex-
pressed as CFUxlog/g. 
Statistical analysis  
Diagnostic graphics were used to test as-
sumptions and outliers. Data were ana-
lyzed using the Linear Mixed Model, 
where group (three levels: C, E, and 
TNBS), time (two levels: T0 and T1) and 
interaction were included as fixed factors. 
Sidak corrections were used for multiple 
comparisons. Results are expressed as 
estimated marginal means ± SE. Fisher's 
exact test was used to compare mortality 
rates. The Kruskal-Wallis analysis, fol-
lowed by the Mann-Whitney test, was 
used to assess DAI and histological 
scores. Bacterial counts were expressed 
and analyzed as log10 CFU per gram of 
colon samples, and only the group effect 
was considered. The inter-group coeffi-
cient of variation (CV) was calculated as 
the ratio of the measurements’ standard 
deviation divided by the mean and multi-
plied by 100. To evaluate the relative 
proportion of each examined bacteria, 
proportions of each bacterial group are 
presented where the total of the exam-
ined bacteria was set at 100%. Statistical 
analyses were performed using SPSS 
Statistics version 20 (IBM, SPSS Inc., 
Chicago, IL, USA). We considered p≤0.05 
as significant and a p value between 0.1 
and 0.05 as a trend. 
 
Results 
Mortality, Body weight, and DAI 
One mouse each from the Saline and 
Ethanol groups died during the experi-
mental period (11.1%; Fisher’s exact 
test: P = 1.000). The BW reduction in the 
control group was not significant (P = 
0.053), whereas ethanol- and TNBS-
treated mice lost 9% and 10% of BW, 
respectively (P = 0.000). DAI was higher 
in the TNBS group than in the Saline 
group (P = 0.008; Figure 1). Ethanol-
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treated mice showed no significant differ-
ences in DAI compared to the Saline and 
TNSB groups, probably as a consequence 
of the high data variability. 
Morphological analysis 
Colons of the saline-treated mice showed 
normal tissue without structural and 
morphological alterations (Figure 2A) 
Contrarily, the colon sections of mice 
from the Ethanol and TNSB groups 
showed a mild and severe grade of in-
flammation, respectively, characterized 
by infiltration of the submucosa mainly 
by lymphocytes and monocytes (Fig. 2B, 
C). The histological score was higher in 
the TNBS group compared to the Saline 
(P = 0.008) and Ethanol (P = 0.032) 
groups. Differences between the Ethanol 
and Saline groups were not significant 
(Figure 3) 
Figure 2: A. Colon histological section af-
ter saline solution treatment. Normal tis-
sue without structural and morphological 
alterations. H&E stain, Magnification x4. 
B. Colon histological section after ethanol 
treatment. Mild grade of inflammation. 
H&E stain, Magnification x4. C. Colon his-
tological section after TNBS treatment. 
Severe grade of inflammation. H&E stain, 
Magnification x4  
Figure 1: Disease activity index (DAI) after treatment with saline (n = 8), ethanol 
(n = 8) and TNBS (n = 9) in CD-1 mice determined through weight loss, stool con-
sistency and bleeding assessment (* P < 0.05 TNBS vs Saline; Mann-Whitney test). 
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Gut microflora 
A significant effect of treatment was ob-
served for all the bacteria examined 
(Figure 4): E. coli (P = 0.000), Entero-
cocci (P = 0.000), Anaerobes (P = 
0.000), Lactobacilli (P = 0.006), Bifido-
bacteria (P = 0.000), and Clostridium 
spp. (P = 0.000). E. coli, Enterococci, 
Anaerobes, and Clostridium spp. counts 
increased after both ethanol and TNBS 
treatments while Lactobacilli and Bifido-
bacteria were reduced in these groups. 
Inter-group CV were 15.4%, 12.0%, 
5.6%, 1.4%, 23.2%, and 6.7% for E. 
coli, Enterococci, Anaerobes, Lactobacilli, 
Bifidobacteria, and Clostridium spp., re-
spectively.  
Figure 5 shows the relative proportions 
of bacterial species in the colon. TNBS 
treatment increased E. coli and Entero-
cocci proportions (P = 0.000) compared 
to the Saline and Ethanol groups. Anaer-
obes were 51% and 32% higher in the 
Ethanol and TNBS groups, respectively, 
compared to saline-treated mice (P = 
0.000). Conversely, the Saline group 
showed a higher proportion of Lactoba-
cilli compared to the Ethanol and TNBS 
groups with 29% and 27% respectively 
(P = 0.000). Bifidobacteria proportion 
was dramatically reduced after both 
ethanol and TNBS treatments compared 
to saline (P = 0.000). Relative propor-
tions of Clostridium spp. were small (< 
0.001%) and there were no differences 
between groups (P = 0.119; data not 
shown). 
 
Discussion 
In the present study, we evaluate the 
effects of TNBS administration on micro-
biota composition, clinical signs and colon 
inflammatory changes in CD1 mice. TNBS 
was dissolved in ethanol and adminis-
tered to mice in order to induce a trans-
mural colitis, reproducing human IBD 
(e.g. Crohn’s disease, at the histological 
and immunologic level). Ethanol is not 
used as a solvent or carrier only, as it 
also aids induction of gut inflammation 
by breaking the mucosal barrier [12]. Our 
data showed a reduction of BW in mice 
treated with ethanol. This initial weight 
loss is due to a nonspecific toxic destruc-
tion of the mucosa by the ethanol, as 
confirmed by histological examination. 
However, these mice showed no signifi-
cant differences in terms of clinical signs, 
evaluated by DAI, when compared to the 
saline-treated animals. Moreover, the 
Ethanol group displayed a lower histo-
logical score than the TNBS group. Our 
Figure 3: Histological score of different treatment groups (** P < 0.01 TNBS vs Sa-
line; * P < 0.05 TNBS vs Ethanol; Mann-Whitney test).  
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findings clearly show that TNBS deter-
mines severe inflammation as demon-
strated by transmural infiltration, high 
DAI and histological score. TNBS is a 
hapten agent that induces a Th1-
mediated immune response involving 
various pro-inflammatory cytokines [12]. 
Nevertheless, the exact mechanisms re-
sponsible for TNBS-induced IBD are 
poorly understood. Various authors have 
proposed different mechanisms to explain 
the pathophysiological features of TNBS-
induced IBD. It has been reported that 
following TNBS administration, L-type 
Ca2+ channels are downregulated and 
Figure 4: Effects of saline, ethanol, and TNBS treatments on colon microbiota (Log 
CFU/gr) in mice. Bars (mean ± SE) with no common letter within a bacterial species 
differ significantly (P < 0.05). 
Figure 5: Effects of saline, ethanol, and TNBS treatments on colon microbiota (Log 
CFU/gr) in mice. Bars (mean ± SE) with no common letter within a bacterial species 
differ significantly (P < 0.05). 
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adenosine triphosphate (ATP)-sensitive 
K+ channels are upregulated in mouse 
gastrointestinal smooth muscle cells. 
These modulations induce hyperpolariza-
tion of the smooth muscle cell mem-
brane, resulting in reduced colonic con-
tractility [19]. A recent study reported 
that exposure to TNBS caused a marked 
decrease in both the mRNA and protein 
expression of aquaporin 3 and 8, sug-
gesting that they may be involved in the 
pathogenesis of IBD [20]. 
Future studies using molecular ap-
proaches, such as that applied in a previ-
ous study [21], are needed to assess 
whether TNBS treatment is able to in-
duce differential gene expression. 
Disruption of the intestinal homeostasis 
and tolerance towards the resident mi-
crobiota is probably the key mechanism 
involved in the development of IBD. In-
deed, the most common site of IBD is 
the colon, where the highest intestinal 
bacterial concentrations are found [1]. 
Over 90% of gut microbiota is composed 
of four major phyla. The most abundant 
phyla are Firmicutes (49–76%), in par-
ticular Clostridium XIV and IV groups, 
and Bacteroidetes (16–23%), followed 
by the less profuse Proteobacteria and 
Actinobacteria phyla [3]. Several lines of 
evidence suggest a key role of the gut 
microbiota in the pathogenesis and per-
sistence of IBD-associated inflammation 
[1,22]. Different studies have shown that 
the gut microbiota in healthy subjects is 
almost temporally stable, whereas in IBD 
patients it is unstable with clear changes. 
In particular, IBD patients present an 
abnormal intestinal microflora (dysbiosis) 
in the faeces and mucosa-associated mi-
crobiota [23]. Dysbiosis is characterized 
by a reduction in the biodiversity of mi-
crobiota, largely due to a decline in the 
diversity of Firmicutes and a depletion of 
some bacterial phyla [24]. In particular, 
in IBD patients, a reduction has been ob-
served in the relative abundance of po-
tentially protective bacteria species, of-
ten referred to as “beneficial bacte-
ria” (Bifidobacteria and Lactobacilli), to-
gether with a concurrent increase in po-
tentially dangerous bacteria (i.e. E. coli 
and sulphate-reducing bacteria) [6]. 
However, whether the dysbiosis is the 
initiating factor that subsequently con-
tributes to the development and persis-
tence of IBD, or a consequence of im-
paired immunity still remains to be eluci-
dated. 
Abnormal microbiota can affect the mu-
cosal immune system. It has been sug-
gested that an abnormal intestinal micro-
biota induces an aberrant immune re-
sponse of the gut immune system, re-
sulting in a chronic inflammation of the 
gastro-intestinal tract in genetically pre-
disposed subjects [25]. While some bac-
teria are inducers of disease, others, 
known as probiotics, are able to reduce 
the inflammatory state. In this context, 
recent studies have reported that supple-
mentation with specific strains of probiot-
ics exerts antigenotoxic, antioxidant, and 
anti-inflammatory effects [13,26,27]. 
The microbiological results of the present 
study indicate that mouse microbiota is 
susceptible to the effects of ethanol and 
TNBS. In particular, the bacteria more 
responsive to such treatments were E. 
coli, Enterococci and Bifidobacteria. 
Count and relative percentage of E. coli 
and Enterococci increased after TNBS 
treatment according to the results ob-
tained by Ondeerdonk et al. [28], who 
found that luminal concentrations of 
these bacterial species correlated to the 
aggressiveness of colitis in B27 trans-
genic rats. Moreover, Conte et al. [29] 
observed an increase in aerobes and E. 
coli in pediatric ulcerative colitis. E. coli 
seems to have a role as a pro-
inflammatory agent. Recent research has 
pointed out that the intestinal microenvi-
ronment in IBD patients would predis-
pose to E. coli proliferation. Moreover, 
this bacterium frequently carries viru-
lence genes related to cytotoxicity and 
genotoxicity, which can contribute to mu-
cosal inflammation and tissue damage 
[30]. 
Our results showed an increase of Clos-
tridum spp. counts after both ethanol and 
TNBS treatment. In the severe combined 
immune deficiency murine model of IBD, 
clostridia-related Gram-positive bacteria 
are essential for the induction of severe 
inflammation. We observed a higher 
count and relative percentage of Lactoba-
cilli and Bifidobacteria in saline-treated 
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mice compared to ethanol- and TNBS-
treated animals. It has been reported 
that a high abundance of Lactobacillus 
spp. and Bifidobacteria strongly correlate 
with low levels of inflammation in mice 
[31]. Similarly, Bullock et al. [32] ob-
served that during active ulcerative coli-
tis, Lactobacillus salivarius and L. mani-
hotivorans were absent in fecal samples 
and reappeared with the colitis in remis-
sion. A decreased Bifidobacterium spp. 
count was also observed in subjects af-
fected by UC and CD in a study con-
ducted by Fyderek et al. [10]. It should 
be noted that the lactobacilli bacteria can 
inhibit intestinal inflammation as demon-
strated by Petrof et al. [5], and that Bifi-
dobacterium spp. participates in immune 
modulation and in intraepithelial lympho-
cyte expansion [33]. 
In conclusion, although dysbiosis has 
been linked to IBD, it is still essential to 
clarify whether abnormal microbiota is 
the initiating factor that contributes to 
the development and persistence of IBD, 
or a secondary symptom of gut inflam-
mation. Therefore, a complete under-
standing of the composition and function 
of the gut microbiota is critical. The re-
sults of the present study demonstrate 
that TNBS treatment changes colonic mi-
crobiota in CD-1 mice by increasing the 
count and relative percentage of detri-
mental bacteria and by decreasing bene-
ficial bacteria. The bacteria more respon-
sive to treatments were E. coli, Entero-
cocci and Bifidobacteria. Our study con-
firms that TNBS-induced colitis is a suit-
able model to study the pathophysiology 
of IBD in mice. Understanding the rela-
tionship between the microbiota and the 
gut immune system should lead to an 
enhanced understanding of the patho-
genesis of IBD and to the development 
of curative treatments. Finally, gut mi-
crobiota composition may be useful as a 
diagnostic tool or biomarker for IBD once 
identification of the specific core micro-
biome will be possible.  
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